It is estimated that in 2017, 554.9 million people in the world suffered from a chronic respiratory disease, a 7.1% global prevalence. That’s a 38.9% increase when compared to 1980. Plugging in the incidence of acute respiratory diseases to the equation gives a clear image of the impact that respiratory diseases have on worldwide healthcare.

Many initiatives have been taken by different organizations and associations (like the American Lung Association’s “LUNG FORCE”), to fight lung diseases worldwide. At PharmaLegacy, we are doing our share of fighting too. We have developed a multitude of preclinical respiratory disease models, designed by scientific experts boasting 15 to 20 years of experience in pharmacology, and our efforts have led to over 400 IND filings.

We have over 1,500 validated models available immediately and can start most studies in under two weeks! Get in touch with our team, and let’s speed the advance of your pipeline into the clinic.


Extensively validated preclinical models:

  • Scientific staff with an average of over 15 years of experience in pharmacology
  • 1,500+ validated animal models of disease spanning 40+ diseases
  • 380,000 square feet of facility space
  • 24/7 access to PharmaLegacy representatives
quality section

Trying to advance your compound from discovery to clinical? PharmaLegacy has the means and the expertise to assist you. Contact us now, and let’s get your pipeline moving.